# Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

> **NCT05484206** · PHASE1 · RECRUITING · sponsor: **Vir Biotechnology, Inc.** · enrollment: 144 (estimated)

## Conditions studied

- Hepatic Impairment
- Cirrhosis

## Interventions

- **DRUG:** VIR-2218
- **DRUG:** VIR-3434

## Key facts

- **NCT ID:** NCT05484206
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-21
- **Primary completion:** 2026-09-25
- **Final completion:** 2027-04-30
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05484206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05484206, "Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05484206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*